within Pharmacolibrary.Drugs.ATC.L;

model L01XX02_1
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 1.8833333333333334e-06,
    adminDuration  = 600,
    adminMass      = 2500 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00186,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.001,
    k12             = 0.029,
    k21             = 0.029
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01XX02_1</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Asparaginase is an enzyme used as an antineoplastic agent primarily in the treatment of acute lymphoblastic leukemia (ALL). It works by depleting the amino acid asparagine, which leukemia cells are unable to synthesize, thereby inhibiting their growth. Asparaginase is approved and in use, especially as a part of multiagent chemotherapy protocols for pediatric and adult ALL.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for pegylated asparaginase (pegaspargase) in children and young adults with ALL, following a single intravenous dose of 2500 IU/m2.</p><h4>References</h4><ol><li><p>Sassen, SD, et al., &amp; van der Sluis, IM (2017). Population pharmacokinetics of intravenous Erwinia asparaginase in pediatric acute lymphoblastic leukemia patients. <i>Haematologica</i> 102(3) 552–561. DOI:<a href=&quot;https://doi.org/10.3324/haematol.2016.149195&quot;>10.3324/haematol.2016.149195</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28250007/&quot;>https://pubmed.ncbi.nlm.nih.gov/28250007</a></p></li><li><p>Fu, CH, &amp; Sakamoto, KM (2007). PEG-asparaginase. <i>Expert opinion on pharmacotherapy</i> 8(12) 1977–1984. DOI:<a href=&quot;https://doi.org/10.1517/14656566.8.12.1977&quot;>10.1517/14656566.8.12.1977</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/17696798/&quot;>https://pubmed.ncbi.nlm.nih.gov/17696798</a></p></li><li><p>Albertsen, BK, et al., &amp; Carlsen, NT (2001). Pharmacokinetics of Erwinia asparaginase after intravenous and intramuscular administration. <i>Cancer chemotherapy and pharmacology</i> 48(1) 77–82. DOI:<a href=&quot;https://doi.org/10.1007/s002800100286&quot;>10.1007/s002800100286</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11488528/&quot;>https://pubmed.ncbi.nlm.nih.gov/11488528</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01XX02_1;
